CEOs, Senior Executives Outline Growth Strategies and Plans at the Virtual DCAT Member Company Announcement Forum
CEOs and senior executives from DCAT Member Companies provide the latest major news from their companies impacting the bio/pharmaceutical manufacturing value chain: manufacturing expansions, mergers and acquisitions, and other key updates.
News from across the bio/pharmaceutical manufacturing value chain
What is the latest news impacting the bio/pharmaceutical manufacturing value chain? As part of Virtual DCAT Week, held July 12-16, 2021, select DCAT Member Companies made major news announcements highlighting manufacturing expansions, mergers and acquisitions (M&A)/M&A integration, and other key strategic updates.
DCAT Week is the premier global event for companies engaged in the bio/pharmaceutical manufacturing value chain and is organized by the Drug, Chemical & Associated Technologies Association (DCAT), a global business-development association. In 2021, DCAT Week was held virtually.
CEOs and senior executives made video announcements to outline their companies’ news. Participating companies included: Boehringer Ingelheim, Cytiva, Catalent, EuroAPI (the planned spinoff from Sanofi of a new European API manufacturing company), Evonik, Lonza, Samsung Biologics, Thermo Fisher Scientific, and WuXi STA. The full listing of companies and the focus of their announcements may be found in the table below.
The video announcements are available for viewing exclusively to DCAT Member Companies, and instructions on how to access the videos may be found here.
Participating companies were selected by the DCAT Member Company Announcement Oversight Task Force based on meeting content and presentation criteria.
|
Virtual DCAT Member Company Announcement Forum: |
|---|
| Aceto: Gilles Cottier, CEO Acquisition and integration of five companies to add to its manufacturing footprint in fine chemicals and life sciences |
| Ajinomoto Bio-Pharma Services: Dr. Mark Cassidy, CEO & President, Ajinomoto Bio-Pharma Services Europe Global expansions in small-molecule API development and manufacturing (including HPAPIs, oligonucleotides and continuous flow chemistry) and fill–finish capacity |
| Asymchem: Elut Hsu, President & Senior Vice President, Business Development Investments in China for two new small-molecule API development and manufacturing facilities |
| Boehringer Ingelheim: Dr. Christian Eckermann, Senior Vice President, Biopharma Austria Update on its new EUR 700-M ($829-M) biomanufacturing facility in Vienna |
| Carbogen Amcis: Mark Griffiths, Dishman Carbogen Amcis Group CEO Updates on its new small-molecule API manufacturing facility in Switzerland and new formulation and fill–finish facility in France |
| Catalent: Karen Flynn, President, Biologics & Chief Commercial Officer Updates on $380-M-plus manufacturing expansions in biologics, cell & gene therapies, drug products, and cold-chain and cryogenic capabilities |
| Cytiva: Emmanuel Ligner, Danaher Group Executive & President and CEO, Cytiva Acquisition and integration of three companies to support digital bioprocessing, lipid nanoparticle technologies, and small-scale aseptic filling |
| DSM Nutritional Products: Kelsey Achenbach, Global Segment Director, Pharma & Medical Nutrition Formed a new strategic partnership to extend its pharmaceutical offering to include cannabinoid APIs |
| Evonik: Dr. Stefan Randl, Vice President, Research, Development & Innovation, Nutrition & Care, Health Care Update on expansion of small-molecule API manufacturing sites in Germany |
| Frontida BioPharm: Eric Kinzler, Ph.D., Study Director, CAT.one testing services for Abuse-Deterrent Formulations Investment to increase capabilities in abuse-deterrent formulations and development |
| Gerresheimer: Niels Düring, Global Executive Vice President, Primary Packaging Plastics US expansion of pharma plastic packaging production capacity |
| Helsinn Advanced Synthesis: Waldo Mossi, General Manager Lab and manufacturing expansion for HPAPIs |
| LGM Pharma: Prasad Raje, CEO Update on integration of acquisition of a drug-product CDMO |
| Lonza: Christian Dowdeswell, Head of Commercial Development, Small Molecules Global expansions in: (1) small-molecule API development and manufacturing (including HPAPIs); (2) large-scale biomanufacturing (CHF 650 M [$703 M] investment); and (3) cell & gene therapy manufacturing |
| Ortec: Christopher Brotherton, President New GMP chemical manufacturing facility in Ireland |
| PharmaBlock: Jing Li, Ph.D., Senior Vice President Combined $155 M facilities expansion in China for small-molecule API and drug-product manufacturing |
| Polpharma: Shlomo Gang, General Director, Polpharma API Small-molecule API manufacturing expansion (including HPAPIs) and cryogenic capabilities |
| Rondo-Pak: Bob Reilley, President & COO Equipment additions for packaging (folding cartons) |
| Samsung Biologics: Segang Park, Vice President, Team Leader, Engineering Project Management, EPCV Update on new $1.47-Bn biomanufacturing facility in Incheon, South Korea |
| Sanofi US SAIS/EuroAPI: Karl Rotthier, CEO, EuroAPI Update on planned spin-off of new European API manufacturing company from Sanofi |
| Sterling Pharma Solutions: Kevin Cook, CEO Acquisition and integration of a CDMO specializing in HPAPIs and bioconjugation and acquisition of US small-molecule API manufacturing site |
| Stevanato Group: Mauro Stocchi, Chief Business Officer $145-M investment for new US manufacturing facility for containment solutions for aseptic manufacturing |
| Thermo Fisher Scientific: Leon Wyszkowski, President, Commercial Operations, Pharma Services Global expansions in development and manufacturing of biologics, cell & gene therapies, and drug products and expansion of clinical supply-chain capabilities |
| Valsynthese: Mara Guzzetti, Ph.D., Senior Executive Vice President, Fine Chemicals New production hydrogenation facility, upgrade of pilot production, and new kilo laboratory for hazardous chemistry |
| WuXi STA: Yu Lu, Vice President, Business Operations, & Jinling Chen, Senior Vice President, Drug Product Division Global expansions in small-molecule API manufacturing (including HPAPIs, oligonucleotides, peptides) and drug-product manufacturing |
